Olmesartan brand name
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Olmesartan Brand Name
Introduction to Olmesartan
Olmesartan is a medication classified as an angiotensin receptor blocker (ARB), primarily used to manage high blood pressure (hypertension) by relaxing blood vessels, allowing blood to flow more easily. It can be used alone or in combination with other antihypertensive drugs.
Brand Names of Olmesartan
Olmesartan is marketed under several brand names, the most notable being Benicar® and Olmetec®. These brands are widely recognized and prescribed for their efficacy in controlling blood pressure.
Pharmacological Properties and Efficacy
Olmesartan medoxomil, the active form of olmesartan, works by inhibiting the actions of angiotensin II on the renin-angiotensin-aldosterone system, which is crucial in the development of hypertension. Clinical trials have demonstrated that olmesartan medoxomil is effective in reducing both systolic and diastolic blood pressure, with a sustained effect throughout the 24-hour dosage interval. It has been shown to be more effective than other ARBs like losartan and irbesartan, and at least as effective as valsartan.
Combination Therapies
For patients who do not achieve adequate blood pressure control with monotherapy, olmesartan is available in fixed-dose combinations with hydrochlorothiazide (HCTZ), marketed as Benicar-HCT® and Olmetec Plus®. These combinations have been proven to enhance antihypertensive efficacy compared to monotherapy.
Physician Prescribing Patterns
A study examining the influence of industry-sponsored meals on physician prescribing patterns found that physicians who received meals promoting olmesartan were more likely to prescribe it over other ACE inhibitors and ARBs. This suggests that marketing efforts can significantly impact the choice of medication prescribed by healthcare providers.
Conclusion
Olmesartan, marketed under brand names such as Benicar® and Olmetec®, is a highly effective ARB for managing hypertension. Its efficacy is well-supported by clinical trials, and it is available in combination with HCTZ for enhanced blood pressure control. However, prescribing patterns can be influenced by pharmaceutical marketing, highlighting the need for awareness in medication selection.
Sources and full results
Most relevant research papers on this topic